Product Name:
CDK6-pY13
Product Number:
ab-pk571
Target Full Name: Cyclin-dependent protein-serine kinase 6
Target Alias: CRK2; Cyclin-dependent kinase 6; Kinase CDK6; PLSTIRE; Serine/threonine protein kinase PLSTIRE; MGC59692; CCDS5628.1; ENSG00000105810
Product Type Specific: CDK6 protein kinase phosphosite-specific antibody
Antibody Code: PK571
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: Y13
Protein UniProt: Q00534
Protein SigNET: CDK6
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human CDK6 sequence peptide Cat. No.: PE-04AJP95
Antibody Immunogen Sequence: DQQ(pY)ECV(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues D10 to V16; in the protein kinase catalytic domain in subdomain I.Y13 phosphorylation inhibits phosphotransferase activity. This is the major in vivo phosphorylation site in CDK6 (≥288 reports from high throughput mass spectrometry studies recorded in PhosphoSitePlus).
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Dog | Mouse.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 34-38 kDa.
Antibody Specificity: High-very high
Antibody Cross Reactivity: No significant cross-reactivities detected in MCF7, and also in HeLa cells, except phenylarsine oxide (PAO) increases 27 kDa protein immunoreactivity in HeLa cells. In sea star oocytes, this antibody cross-reacted with phospho-CDK1 and phospho-ERK1.
Related Product 1: CDK6 (10-16) pY13 antibody blocking peptide (Cat. No.: PE-04AJP95)
Related Product 2: CDK4/6Selectide kinase substrate peptide (Cat. No.: PE-01BGP99)
Related Product 3: RNA polymerase II-CT KinSub - heptapeptide repeat from C-terminus peptide; CDKtide protein kinase substrate peptide
Related Product 4: CDK6 Y24 phosphorylation antibody (Cat. No.: AB-PK572)
Scientific Background: CDK6 is a cyclin-dependent, protein-serine/threonine kinase of the CMGC group and CDK family. It is involved in cell cycle regulation and differentiation, which promotes G1/S transition. It regulates cell proliferation, differentiation, and tumorigenesis by phosphorylating the retinoblastoma protein (Rb). Beyond cell cycle control, CDK6 plays a role in differentiation, prevents senescence, and aids in hematopoiesis. Its activity is controlled by association with D-type cyclins (D1, D2, D3) and inhibition by the INK4 family of inhibitors (e.g., p16). Phosphorylation at Thr-177 increases phosphotransferase activity. It is primarily active in the nucleus of proliferating cells, although it isfound in the cytoplasm of some cell types. Germline mutations in CDK6 are hypothesized to lead to a predisposition to melanoma. A197T mutation is found in family with autosomal recessive primary microcephaly-12 (MCPH12). Overexpression of CDK6 is common in various cancers (e.g., breast cancer, lymphoma, leukemia), often driving uncontrolled growth and angiogenesis, making it a key therapeutic target. In addition to cancer, CDK6 is vital for hematopoiesis (blood cell formation) and neural development, with mutations linked to primary microcephaly.This description may include information annotated by UniProt and/or Google AI.